W nt signaling has been implicated to be a driving force in survival and proliferation in various types of cancer. As a result, many investigators are finding strategies to interfere with the activity of Wnt signaling intermediates. Targeting secretion of Wnt factors is one such promising strategy. Posttranslational acylation by PORCN is required for the secretion of virtually all Wnt factors. 2, 3 The Wnt signaling pathway consists of a b-and g-catenin-dependent canonical pathway and calcium ion-and small GTPase-dependent non-canonical pathways. The controversy surrounding the role of Wnts in hematopoiesis stems from observations in knockout mouse models, which showed that mediators of the Wnt pathway were essential for proper lymphocyte development. Surprisingly, however, normal hematopoiesis as well as lymphopoiesis occurs in the absence of both central mediators of canonical Wnt signaling: b-and g-catenin. 4, 5 In addition, transplantation of long-term hematopoietic stem cells (LT-HSCs) lacking both catenins show essentially normal hematopoietic regeneration, with normal development of all lymphocyte lineages, both in primary and secondary recipients. Nevertheless, expression of the activated S33Y form of b-catenin or upstream factors of the canonical Wnt signaling pathway shows that increased catenin activation interferes with normal progenitor production and maturation as well as decreases LT-HSC activity in a transplantation setting. 6, 7 Some of the confusion regarding the lack of effect of catenin deletion and the hematopoiesis disruption at catenin activation was lifted in an elegant study in which Apc, a negative catenin regulator, was dosed. This study showed that LT-HSC is enhanced by low-level (twofold) catenin activation, whereas progressive activation impairs LT-HSC self-renewal in favor of enhanced myelopoiesis and lymphopoiesis, which, at further catenin activation, both show impaired differentiation. However, the paper by Kabiri and coworkers also raises more fundamental questions about the nature of Wnt signaling, and its impact on cellular behavior. For instance, they find that despite deletion of the Porcn gene, transcription of the catenindependent Wnt targets Axin2, Ccnd1, and Myc, are still activated as if it is "business as usual." Although (b-or g-) catenin activation was not specifically studied in this paper, it seems likely that activation of catenin-dependent transcription does occur. It is possible that autocrine-acting Wnt factors do not need to be secreted to be active. 
A vaccine against HTLV-1 HBZ makes sense -----------------------------------------------------------------------------------------------------Renaud Mahieux EQUIPE LABELISÉE LIGUE CONTRE LE CANCER, INSERM U1111-CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UMR5308
In this issue of Blood, Sugata et al report that vaccination against human T-cell leukemia virus type 1 (HTLV-1) basic leucine zipper (bZIP) factor (HBZ) could be used for immunotherapy in adult T-cell leukemia-lymphoma (ATL) patients.
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T he HTLV-1 human oncogenic retrovirus was discovered more than 30 years ago. It infects 5 to 10 million individuals and is the etiologic agent of both neurologic (eg, HTLV-1-associated myelopathy/tropical spastic paraparesis [HAM/TSP]) and hematologic (eg, ATL) diseases. Although a recent report suggests that it possible to decrease HTLV-1 proviral load in carriers at risk for developing a disease by using a combination of reverse transcriptase and histone deacetylase inhibitors, 2 most treatments, when delivered to ATL and HAM/TSP patients, show a modest rate of success. 3, 4 The risk of developing ATL is linked to infection early in life. However, transmission could be prevented by screening blood products and avoiding maternal transmission via breast milk. It may be possible to create an anti-HTLV-1 therapeutic vaccine for those who are infected and who develop ATL. Given the extreme genetic stability of HTLV-1, which is linked to the clonal expansion of infected cells rather than to the use of the viral reverse transcriptase, 5 it was originally believed that developing an anti-HTLV-1 vaccine would be an easy task. 6 The viral envelope is required to bind to the cell receptor(s) and elicits both a humoral and a cellular immune response in infected individuals. In addition, neutralizing antibodies directed toward the viral envelope have been described. Thus, viral envelope-recombinant vaccinia or adenoviruses as well as viral envelope naked DNA and chimeric peptides were generated and used to immunize mice, rats, rabbits, or monkeys in the 1990s and early 2000s. 7, 8 However, partial protection was observed in only a limited number of animals after challenge with HTLV-1-infected cells. An animal model in which ATL or HAM/TSP development could be observed at a reasonable frequency was also lacking at that time and did not allow the development of therapeutic vaccine. Adding another level of complexity, it is well established that HTLV-1 viral expression is extremely low in human ATL patients because of provirus deletion or methylation of the 59 long terminal repeat. This issue needs to be addressed when designing a therapeutic vaccine. The discovery of HBZ, which is encoded by an antisense viral transcript, 9 challenged this paradigm. Indeed, HBZ is expressed in infected cells isolated from asymptomatic carriers but, more importantly, in malignant cells from ATL patients. In addition, HBZ transgenic mice develop lymphoma. Thus, this protein is oncogenic and might be considered a target for anti-ATL immunotherapy. Interestingly enough, recent in silico results also suggest that the immune response against HBZ influences proviral load.
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The study by Sugata et al 1 aimed to determine whether a recombinant vaccinia virus expressing HBZ as an antigen HBZ-specific effector cells improved the survival ratio in an HBZ-induced ATL model. Naïve mice were inoculated intraperitoneally with lymphoma cells expressing HTLV-1 HBZ and then with peptide-stimulated splenocytes from rVV-HBZ-vaccinated mice. Survival curves were analyzed by the Kaplan-Meier method, and statistical differences were calculated by the log-rank test; *P , .05 by the logrank test. See Figure 4B in the article by Sugata et al that begins on page 1095.
